Reportlinker Adds Global Protein Therapeutics Market Analysis
NEW YORK, May 24 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Protein Therapeutics Market Analysis
http://www.reportlinker.com/p0200068/Global-Protein-Therapeutics-Market-Analysis.html
Protein therapeutics have changed the face of modern medicine in the past decade as they provide innovative and effective therapies for numerous previously refractory illnesses. Besides, the fast developments in protein therapeutics have had a positive impact on the pharmaceutical and biotech industries. The number of protein-based pharmaceuticals reaching the marketplace has exponentially increased over the past few years. With increasing demand for innovative protein therapeutics each year, existing as well as new players are making huge investment into this market. Moreover, new developments in manufacturing & production technology have led to significant advancements in protein manufacturing and production.
According to our new research report "Global Protein Therapeutics Market Analysis", the global protein therapeutics market is expected to grow at a CAGR of around 12% during 2010-2013. At present, the market is characterized by high cost treatments therapy and healthcare insurance which in turn helping the companies to generate more revenue. With the advent of new technologies and genetic and chemical techniques, the protein therapeutics industry has ensured a competitive edge in developing improved protein and peptide based therapeutics.
Our report has found that the market is presently dominated by Monoclonal Antibodies. With double-digit growth projected for future, this segment is expected to bolster its dominant position. Smaller companies are likely to become more visible as their products move closer to regulatory approval.
Further, Insulin, Interferon Beta, G-CSF and coagulation factors are also exhibiting healthy growth rates. One of the biggest opportunity areas in the protein therapeutics market is bio-generics which are expected to create a multi-billion dollar market in future. The pharmaceutical contract research and manufacturing market is expected to grow at an unmatched rate on account of high cost factor.
The report provides extensive information and rational analysis of the global protein therapeutics market. It has thoroughly examined current market trends, industrial developments and competitive landscape to enable clients understand the market structure and its progress in coming years. The report also gives an insight into the segment-wise market trends prevailing at the regional level to provide an overview of developments taking place in these segments across the world.
The report also facilitates in comprehending the market inhibitors that need collective and strategic evaluation to foster growth in the protein therapeutics market. The key player section includes information about the business operation and SWOT analysis of leading firms. The forecast given in the report is based on correlation between the market trends and drivers.
1. Analyst View
2. Global Proteins Therapeutic Market
2.1 Market Analysis
2.1.1 Market Size
2.1.2 Proteins Therapeutic Market vs Pharmaceutical Market
2.1.3 Market Segmentation
2.2 Future Outlook (2010-2013)
3. Industry Performance
3.1 Monoclonal Antibodies (mAbs)
3.1.1 Market Size
3.1.2 By Application
3.1.3 Key Geographical Markets
3.1.4 Key Players and Drugs
3.1.5 Industry Analysis
3.1.6 Future Outlook (2010-2013)
3.2 Erythropoietin (EPO)
3.2.1 Market Size
3.2.2 By Application
3.2.3 Key Geographical Markets
3.2.4 Key Players and Drugs
3.2.5 Industry Analysis
3.2.6 Future Outlook (2010-2013)
3.3 Insulin
3.3.1 Market Size
3.3.2 By Application
3.3.3 Key Geographical Markets
3.3.4 Key Players and Drugs
3.3.5 Industry Analysis
3.3.6 Future Outlook (2010-2013)
3.4 Interferon (IFN)
3.4.1 Market Size
3.4.2 Key Geographical Markets
3.4.3 Key Players and Drugs
3.4.4 Industry Analysis
3.4.5 Future Outlook (2010-2013)
3.5 Human Growth Hormone (HGH)
3.5.1 Market Size
3.5.2 By Application
3.5.3 Key Geographical Markets
3.5.4 Key Players and Drugs
3.5.5 Industry Analysis
3.5.6 Future Outlook (2010-2013)
3.6 Blood Clotting Factor
3.6.1 Market Size
3.6.2 Key Players and Drugs
3.6.3 Industry Analysis
3.6.4 Future Outlook (2010-2013)
3.7 Follicle Stimulating Hormone (FSH)
3.7.1 Market Size
3.7.2 Key Players and Drugs
3.7.3 Industry Analysis
3.7.4 Future Outlook (2010-2013)
3.8 Granulocyte Colony Stimulating Factor (G-CSF)
3.8.1 Market Size
3.8.2 Key Players and Drugs
3.8.3 Industry Analysis
3.8.4 Future Outlook (2010-2013)
4. Emerging Market Trends
4.1 Biogenerics
4.2 Contract Research Outsourcing
4.3 Contract Manufacturing
4.4 Nanotechnology-enabled Drug Delivery Market
4.5 Healthcare Insurance
4.6 High Approval Rate
5. Growth Inhibitors
5.1 High R&D Cost
5.2 High Price
5.3 High Failure Rates in Phase-3 Clinical Trials
5.4 Insurance Reimbursements
5.5 Lack of Predictability in the Operating Environment
6. Key Players
6.1 Johnson & Johnson
6.2 Biogen Idec Inc.
6.3 Eli Lilly & Company
6.4 Sanofi-Aventis
6.5 Merck Serono S.A
6.6 Roche Group
6.7 Amgen Inc.
List of Figures:
Figure 2-1: Global - Proteins Therapeutic Market (Billion US$), 2008 & 2009
Figure 2-2: Global - Forecast for Proteins Therapeutic Vs Pharmaceutical Market (Billion US$), 2010
Figure 2-3: Global - Proteins Therapeutic Market by Segment (%), 2009
Figure 2-4: Global - Forecast for Proteins Therapeutic Market (Billion US$), 2010-2013
Figure 2-5: Global - Forecast for Proteins Therapeutic Market by Segment (%), 2013
Figure 3-1: Global - Monoclonal Antibodies Market (Billion US$), 2008 & 2009
Figure 3-2: Global - Monoclonal Antibodies Market by Segment (%), 2009
Figure 3-3: Global - Use of Monoclonal Antibodies in Cancer Treatment (Billion US$), 2008-2010
Figure 3-4: Global - Use of Monoclonal Antibodies in Rheumatoid Arthritis Treatment (Billion US$), 2008-2010
Figure 3-5: Global - Use of Monoclonal Antibodies in Other Chronic Diseases Treatment (Billion US$), 2008-2010
Figure 3-6: US - Monoclonal Antibodies Market (Billion US$), 2007-2009
Figure 3-7: US - Forecast for Monoclonal Antibodies Market (Billion US$), 2010-2013
Figure 3-8: Europe - Monoclonal Antibodies Market (Billion US$), 2007-2009
Figure 3-9: Europe - Forecast for Monoclonal Antibodies Market (Billion US$), 2010-2013
Figure 3-10: Europe - Forecast for Monoclonal Antibodies Market by Application (%), 2011
Figure 3-11: Japan - Monoclonal Antibodies Market (Billion JPY), 2007-2009
Figure 3-12: Japan - Forecast for Monoclonal Antibodies Market (Billion JPY), 2010-2013
Figure 3-13: Global - Share of Key Players in Monoclonal Antibodies Market (2009)
Figure 3-14: Global - Top Selling Monoclonal Antibodies (Billion US$), 2009
Figure 3-15: Global - Forecast for Monoclonal Antibodies Market (Billion US$), 2010-2013
Figure 3-16: Global - Erythropoietin Market (Billion US$), 2007-2009
Figure 3-17: Global - Number of Patients on Dialysis (Million), 2008 & 2009
Figure 3-18: Global - Breakup of Patients on Dialysis by Region (%), 2009
Figure 3-19: Global - Number of New Cancer Cases (Million), 2008 & 2030
Figure 3-20: Global - Breakup of New Cancer Cases by Region (%), 2008
Figure 3-21: Europe - Erythropoietin & Untapped Erythropoietin Market for Chemotherapy (Million Euro)
Figure 3-22: Europe - Erythropoietin Market (Billion US$), 2009-2013
Figure 3-23: Europe - Erythropoietin Market in Renal Anemia Treatment (Million US$), 2007-2009
Figure 3-24: Europe - Erythropoietin Market in Oncology Treatment (Million US$), 2007-2009
Figure 3-25: Europe - First Generation Erythropoietin Patent Expiry by Major Country
Figure 3-26: Japan - Erythropoietin Market (Billion JPY), 2007-2009
Figure 3-27: Global - Forecast for Erythropoietin Market (Billion US$), 2010-2013
Figure 3-28: Europe - Forecast for Share of Oncology and Renal Anemia in Erythropoietin Market (2016)
Figure 3-29: Global - Insulin Market (Billion US$), 2007-2009
Figure 3-30: India - Forecast for Number of Diabetic Patients (Million), 2010 & 2030
Figure 3-31: India - Insulin Market (Million US$), 2007-2009
Figure 3-32: India - Forecast for Share of Key Players in Insulin Market (2010)
Figure 3-33: China - Insulin Market (Billion RMB), 2006-2009
Figure 3-34: China - Share of Key Players in Insulin Market (Q3 2008)
Figure 3-35: US - Insulin Market (Billion US$), 2006-2009
Figure 3-36: US - Share of Key Players in Insulin Market (Q3 2009)
Figure 3-37: Russia - Insulin Market (Million US$), 2007-2009
Figure 3-38: Russia - Share of Key Players in Insulin Market
Figure 3-39: Russia - Insulin Market by Channel of Sales (%), 2007
Figure 3-40: Japan - Insulin Market (Billion JPY), 2007-2009
Figure 3-41: Japan - Share of Key Players in Insulin Market (2009)
Figure 3-42: Germany - Share of Insulin in Genetically Manufactured Pharmaceuticals Market (2007)
Figure 3-43: Brazil - Insulin Market (Million BRL), 2007-2009
Figure 3-44: Brazil - Share of Key Players in Insulin Market (2007)
Figure 3-45: Global - Share of Key Players in Insulin Market (2009)
Figure 3-46: Share of Novo Nordisk in Insulin Market of US, Europe and Japan (2009)
Figure 3-47: Global - Share of Brands in Insulin Market (2009)
Figure 3-48: Global - Forecast For Number of Diabetic Patients (Million), 2010 & 2030
Figure 3-49: Global - Forecast for Insulin Market (Billion US$), 2010-2013
Figure 3-50: Global - Interferon Market (Billion US$), 2007-2009
Figure 3-51: Global - Share of Alpha and Beta in Interferon Market (2009)
Figure 3-52: Global - Interferon Alpha Market (Billion US$), 2007-2009
Figure 3-53: Global - Forecast for Hepatitis B Treatment Market (Billion US$), 2010-2013
Figure 3-54: Global - Hepatitis C Treatment Market (Billion US$), 2007-2013
Figure 3-55: Global - Interferon Beta Market (Billion US$), 2007-2009
Figure 3-56: Global - Multiple Sclerosis Treatment Market (Billion US$), 2008 & 2009
Figure 3-57: US - Interferon Market (Billion US$)
Figure 3-58: Europe - Interferon Market (Million US$)
Figure 3-59: Japan - Interferon Market (Billion JPY), 2007-2009
Figure 3-60: Global - Forecast for Interferon Market (Billion US$), 2010-2013
Figure 3-61: Global - Human Growth Hormone Market (Billion US$), 2007-2009
Figure 3-62: US, Europe & Japan - Number of Patients with Pediatric Growth Hormone Deficiency ('000)
Figure 3-63: Global - Share of Growth Hormones in Treatment of Pediatric Short Stature
Figure 3-64: Global - Adult Growth Hormone Deficiency Market (Million US$)
Figure 3-65: Global - Human Growth Hormone Market by Region (%), 2007
Figure 3-66: US - Human Growth Hormone Market (Billion US$), 2007-2009
Figure 3-67: Japan & Europe - Human Growth Hormone Market (Million US$), 2007
Figure 3-68: Global - Share of Key Players in Human Growth Hormone Market (2009)
Figure 3-69: Global - Forecast for Human Growth Hormone Market (Billion US$), 2010-2013
Figure 3-70: Global - Blood Clotting Factor Market (Billion US$), 2007-2009
Figure 3-71: Global - Share of Blood Clotting Factor Market by Segment (2009)
Figure 3-72: Global - Share of Key Players in Blood Clotting Factor Market (2009)
Figure 3-73: Global - Forecast for Blood Clotting Factor Market (Billion US$), 2010-2013
Figure 3-74: Global - Follicle Stimulating Hormone Market (Billion US$), 2007-2009
Figure 3-75: Global - Forecast for Follicle Stimulating Hormone Market (Billion US$), 2010-2013
Figure 3-76: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2007 - 2009
Figure 3-77: US - Share in Global Granulocyte Colony Stimulating Factor Market
Figure 3-78: Global - Forecast for Granulocyte Colony Stimulating Factor Market (Billion US$), 2010-2013
Figure 4-1: Global - Sales of Biologics by Year of Patent Expiration (Billion US$), 2008-2015
Figure 4-2: Global - Biogenerics Market (Billion US$), 2007 & 2011
Figure 4-3: Global - Contract Research Outsourcing Market (Billion US$), 2008 & 2013
Figure 4-4: Global - Forecast for Pharmaceutical Contract Manufacturing Market (Billion US$), 2010-2012
Figure 4-5: Global - Nanotechnology-enabled Drug Delivery Market (Billion US$), 2007 & 2012
Figure 4-6: Global - Approval Rate for Biopharmaceuticals and Conventional Pharmaceuticals
Figure 5-1: Global - Comparison of Annual Cost of Biotech Drugs to Traditional Drugs (US$)
Figure 5-2: Global - Failure Rate in Phase-3 Clinical Trials of Biotech and Traditional Drugs
List of Tables:
Table 3-1: Global - Key Players and Drugs in Erythropoietin Alfa Market (Million US$), 2009
Table 3-2: Global - Key Players and Drugs in Erythropoietin Beta Market (Million US$), 2009
Table 3-3: Global - Key Players and Drugs in Darbepoetin Market (Million US$), 2009
Table 3-4: China - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-5: US - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-6: Russia - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-7: Japan - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-8: Germany - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-9: Brazil - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-10: Global - Key Players and Drugs in Interferon Alpha Market (Million US$), 2009
Table 3-11: Global - Key Players and Drugs in Interferon Beta Market (Million US$), 2009
Table 3-12: Global - Key Players and Drugs in Human Growth Hormone Market (Million US$), 2009
Table 3-13: Global - Key Players and Drugs in Blood Clotting Factor Market (Million US$), 2009
Table 3-14: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Million US$), 2009
Table 3-15: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Million US$), 2009
Table 4-1: US & Europe - Patent Expiry Dates for Recombinant Biologics
Table 4-2: US & EU - Forecast for Biogenerics Market by Segment (Million US$), 2010
Table 6-1: Eli Lilly - Strengths & Weaknesses
Table 6-2: Roche Holding Ltd. - Strengths & Weaknesses
To order this report: Drug and Medication Industry: Global Protein Therapeutics Market Analysis
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article